USFDA issues Form 483 with 5 observations to Aurobindo Pharma's Andhra unit

Aurobindo Pharma said the USFDA issued a Form 483 with five procedural observations after inspecting Unit-IV of its subsidiary APL Healthcare in Andhra Pradesh from December 8–17, 2025. The company said it will respond within stipulated timelines and remains committed to quality standards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xvuwkpa
via IFTTT